2014 | Nanjing Research & Development Center Established |
2015 2016 | Angel Round of Financing Completed: Series-Pre-A Financing |
2017 | LBL-007 Entered Preclinical Research |
2018 | Completed Series-A Financing |
LBL-003 Entered Preclinical Research |
2019 | LBL-007 Obtained Clinical Clearance from China NMPA |
LBL-015 Entered Preclinical Research | |
Signed a Licensing-out Agreement with Pneuma |
2020 | Completed Series-B Financing |
LBL-003 and LBL-007 Obtained Clinical Clearance from U.S. FDA | |
Signed Collaboration Agreement with Junshi Biosciences Co., Ltd and Xihu Biologicals |
2021 | Completed Series-C Financing |
LBL-024, LBL-015 and LBL-019 Obtained Clinical Clearance from U.S. FDA and China NMPA | |
LBL-003 Obtained Clinical Clearance from China NMPA | |
Announced Global License and Collaboration Agreement with BeiGene for Anti-LAG-3 Antibody LBL007 |
2022 | LBL-033 IND filed |
Jiangbei Development & Production Center officially opened with GMP capabilities |
2023 | LBL-033 and LBL-034 Obtained Clinical Clearance from U.S. FDA and China NMPA |